FIELD: biotechnology.
SUBSTANCE: described is an adeno-associated viral (AAV) vector for treating or preventing a complement-mediated disorder comprising a nucleotide sequence encoding factor I or a fragment thereof, where the fragment is capable of splitting C3b to iC3b.
EFFECT: invention extends the range of agents for treating or preventing complement-mediated disorder.
27 cl, 14 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2017 |
|
RU2768982C2 |
| FUSED PROTEIN OF SHORT FORM OF CONE VIABILITY FACTOR OBTAINED FROM RODS, AND HYDROPHILIC PEPTIDE | 2017 |
|
RU2773368C2 |
| AAV VECTORS AIMED AT THE CENTRAL NERVOUS SYSTEM | 2015 |
|
RU2727015C2 |
| GENETIC CONSTRUCT | 2016 |
|
RU2734678C2 |
| COMPOSITION FOR RELIEVING OR TREATING PAIN | 2017 |
|
RU2725830C1 |
| GENETIC STRUCTURE FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE | 2018 |
|
RU2757932C2 |
| NUCLEIC ACID CONSTRUCTIONS AND VECTORS FOR GENOTHERAPY FOR TREATING WILSON'S DISEASE AND OTHER CONDITIONS | 2015 |
|
RU2745567C2 |
| RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
| NEW LIVER TARGETING ADENO-ASSOCIATED VIRAL VECTORS | 2019 |
|
RU2793735C2 |
| MODIFIED FACTOR IX, AS WELL AS COMPOSITIONS, METHODS AND OPTIONS FOR THE USE OF GENE TRANSFER INTO CELLS, ORGANS AND TISSUE | 2016 |
|
RU2811445C2 |
